{'52WeekChange': 0.30033553,
 'SandP52WeekChange': None,
 'address1': '60 Avenue Rockefeller',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 8.81,
 'askSize': 1000,
 'averageDailyVolume10Day': 812,
 'averageVolume': 4212,
 'averageVolume10days': 812,
 'beta': 1.498837,
 'beta3Year': None,
 'bid': 7.32,
 'bidSize': 1100,
 'bookValue': 10.639,
 'category': None,
 'circulatingSupply': None,
 'city': 'Lyon',
 'companyOfficers': [],
 'country': 'France',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 8,
 'dayLow': 8,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 143500288,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '33 4 78 75 56 29',
 'fiftyDayAverage': 8.526286,
 'fiftyTwoWeekHigh': 12,
 'fiftyTwoWeekLow': 3.5,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 9750306,
 'forwardEps': -2.76,
 'forwardPE': -2.8985507,
 'fromCurrency': None,
 'fullTimeEmployees': 217,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.0039,
 'heldPercentInstitutions': 0.07053,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/erytech.com',
 'longBusinessSummary': 'ERYTECH Pharma S.A., a clinical-stage '
                        'biopharmaceutical company, develops red blood '
                        'cell-based therapeutics for cancer and orphan '
                        "diseases. The company's lead product candidate is "
                        'eryaspase, which is in Phase III clinical development '
                        'for the treatment of second-line pancreatic cancer '
                        'and in Phase II stage for the treatment of '
                        'triple-negative breast cancer. It also engages in '
                        'developing erymethionase, a preclinical product '
                        'candidate that consists of methionine-gamma-lyase '
                        'encapsulated in red blood cells to target '
                        'methionine-dependent cancers. ERYTECH Pharma S.A. has '
                        'research collaborations with the Fox Chase Cancer '
                        'Center to advance the preclinical development of '
                        'erymethionase for the treatment of homocystinuria; '
                        "and Queen's University of Canada to advance the "
                        'preclinical development of eryminase for the '
                        'treatment of arginase-1-deficiency. The company was '
                        'founded in 2004 and is headquartered in Lyon, France.',
 'longName': 'ERYTECH Pharma S.A.',
 'market': 'us_market',
 'marketCap': 145912000,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_24677080',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1577750400,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 8,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '33 4 78 74 44 38',
 'previousClose': 7.75,
 'priceHint': 2,
 'priceToBook': 0.7519504,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 8,
 'regularMarketDayLow': 8,
 'regularMarketOpen': 8,
 'regularMarketPreviousClose': 7.75,
 'regularMarketPrice': 8,
 'regularMarketVolume': 207,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 17937500,
 'sharesPercentSharesOut': 0,
 'sharesShort': 1012,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1538,
 'shortName': 'Erytech Pharma S.A.',
 'shortPercentOfFloat': None,
 'shortRatio': 0.11,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'ERYP',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.786,
 'twoHundredDayAverage': 7.2477555,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'b27b826c-3b42-357d-95c0-ef22a381273a',
 'volume': 207,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.erytech.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '69008'}